Warwick researchers develop new vehicle for drug release

Published: 1-Feb-2011
Drug Delivery Research & Development Pharmaceutical

Plankton inspires creation of ‘stealth’ armour for slow release microscopic drug vehicles

Researchers at the University of Warwick in the UK have devised a simple way of giving drug-bearing polymer vesicles (microscopic polymer-based sacs of liquid) their own ‘armoured protection’ after being inspired by the ability of some forms of plankton and bacteria to build an extra natural layer of nanoparticle-like armour.

The scientists have been able to decorate these hollow structures with a variety of nanoparticles, opening a new strategy in the design of vehicles for drug release, for example by giving the vesicle ‘stealth’ capabilities which can avoid the body’s defences while releasing the drug.

Advances in polymerisation have boosted the creation of vesicles made from polymer molecules. Such vesicles have special chemical and physical properties, which make them potential drug delivery vehicles.

The University of Warwick team believed that more strength and tailored properties could be given to the vesicles if they could add an additional layer of colloidal ‘armour’ made from a variety of nanoparticles.

Lead researcher, Associate Professor Stefan Bon, said: ‘We took our inspiration from nature, in how it adds protection and mechanical strength in certain classes of cells and organisms. In addition to the mechanical strength provided by the cytoskeleton of the cell, plants, fungi, certain bacteria have an additional cell wall as outermost boundary.

‘Organisms that particularly attracted our interest were those with a cell wall composed of an armour of colloidal objects – for instance bacteria coated with S-layer proteins, or phytoplankton, such as the coccolithophorids, which have their own CaCO3-based nano-patterned colloidal armour.’

The Warwick researchers hit on a simple and effective method of adding different types of extra armour to the polymer-based vesicles. One example was a packed layer of microscopic polystyrene balls. Because the polystyrene balls had a crystalline-like ordered structure, the researchers could design a vesicle with an additional and precise permeable reinforced barrier for drug release.

The researchers used the same technique to add a gelatine-like polymer to provide ‘stealth’ armour to shield vesicles from unwanted attention from the body’s immune system while it slowly released its drug treatment.

This particular coating (a poly((ethyl acrylate)-co-(methacrylic acid)) hydrogel) absorbs so much surrounding water into its outer structure that it may be able to fool the body’s defence mechanism into believing it is in fact just water.

See more

You may also like

Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

Read more
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies

Trending Articles

  1. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  4. Sygnature Discovery strengthens in vivo pharmacology leadership with appointment of Susanne Back The appointment of Susanne Back as Head of In Vivo Pharmacology will further strengthen its bioscience leadership and reinforcing its commitment to delivering high-quality, integrated drug discovery solutions for customers worldwide
  5. AstraZeneca's tozorakimab succeeds in third pivotal Phase III COPD trial The positive results have shown that tozorakimab significantly reduced moderate-to-severe COPD exacerbations, adding to the earlier positive results from the OBERON and TITANIA trials and further supporting its potential as a first-in-class IL-33-targeting biologic

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Research & Development

Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer

The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Manufacturing

Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases

Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
Research & Development

NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing

The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Subscribe now